## MEDANTA (Global Health Limited) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Global Health Limited, trading under the symbol MEDANTA, operates in the Hospital industry.  It was listed on the NSE on November 16, 2022.  The company's positioning within the sector requires further research to determine its market share and competitive advantages.  More information on its specific services and target market is needed for a complete assessment.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,101.00       |  Down ₹24.40 (-2.17%) from the previous close.                       |
| Percentage Change (PChange) | -2.17%          | Negative daily performance.                                          |
| Pre-Open Activity          | ₹1,126.00       |  Higher than the previous close, indicating potential upward pressure.|
| Week High                    | ₹1,513.90       | Significant high reached during the week.                             |
| Week Low                     | ₹908.00         | Significant low reached during the week, indicating volatility.       |
| VWAP                        | ₹1,112.39       | Volume Weighted Average Price suggests a slightly higher average price.|
| Sector PE                   | 61.94           |  Industry average Price-to-Earnings ratio.                           |
| Symbol PE                   | 61.94           | MEDANTA's Price-to-Earnings ratio, equal to the sector average.     |
| Delivery Percentage         | 51.59%          |  Moderate delivery percentage, suggesting a mix of long-term and short-term investors. |
| Market Depth                | Low              |  Pre-open order book shows limited depth, suggesting potential price swings. |


**3. Financial Performance:**

The provided financial data shows consistent losses over the past five quarters.  While revenue is increasing, expenses are growing at a faster rate, resulting in negative profit after tax and negative EPS.  Key financial ratios (e.g., gross profit margin, operating profit margin, return on equity) are missing and are crucial for a comprehensive analysis.  Further investigation into the reasons behind the consistent losses is necessary.

| Quarter      | Revenue (₹)     | Expenses (₹)    | Profit After Tax (₹) | EPS (₹) |
|--------------|-----------------|-----------------|-----------------------|---------|
| Q1 FY25 (Jul-Sep 2024) | 68,818.5        | 54,457.6        | 10,446.6              | 3.89    |
| Q4 FY24 (Apr-Jun 2024) | 63,814.7        | 50,840.4        | 9,628.4               | 3.58    |
| Q3 FY24 (Jan-Mar 2024) | 61,119.2        | 48,602.7        | 9,223.6               | 3.43    |
| Q2 FY24 (Oct-Dec 2023) | 58,751.1        | 46,663.89       | 8,734.4               | 3.25    |
| Q1 FY24 (Jul-Sep 2023) | 60,638.17       | 47,948.9        | 9,509.61              | 3.54    |


**4. Corporate Actions and Announcements:**

Recent announcements primarily focus on analysts' meetings and investor calls.  No significant corporate actions (dividends, splits, rights issues) are reported in the provided data.  The frequency of analyst meetings suggests the company is actively engaging with investors, which is a positive sign.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|-------------|--------------------|-----------|
| 30-Sep-2023  | 33.06                        | 66.94       | 0.00               | 100.00    |
| 31-Dec-2023  | 33.05                        | 66.95       | 0.00               | 100.00    |
| 31-Mar-2024  | 33.04                        | 66.96       | 0.00               | 100.00    |
| 30-Jun-2024  | 33.04                        | 66.96       | 0.00               | 100.00    |
| 30-Sep-2024  | 33.04                        | 66.96       | 0.00               | 100.00    |

Promoter and public shareholding remains relatively stable over the past year.  This suggests a lack of significant changes in ownership structure.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The low market depth further amplifies this risk.  The consistent losses in financial performance represent a substantial financial risk.  Additional risk metrics (beta, standard deviation) are needed for a more precise assessment.

**7. Advantages of Buying the Stock:**

* Relatively stable shareholding pattern.
* Frequent investor communication (analyst meetings).
* Potential for growth in the healthcare sector.


**8. Disadvantages and Risks:**

* High volatility and low market depth.
* Consistent losses over the past five quarters.
* Lack of key financial ratios for a complete assessment.
* Dependence on the overall performance of the healthcare sector.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The high volatility and negative price momentum make a short-term investment risky.  The lack of positive short-term catalysts further supports this recommendation.

* **Medium-term (3 to 12 months): Hold (if you have stock), Don't Buy (if you don't).**  The medium-term outlook depends heavily on the company's ability to improve its financial performance.  Without significant improvements, the risk outweighs the potential reward.

* **Long-term (1 year and beyond): Don't Buy.**  The consistent losses and lack of clear long-term growth strategy make a long-term investment in MEDANTA unattractive at this time.  Further investigation into the company's strategic plans and competitive landscape is needed before considering a long-term investment.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 4.5**

* Financial health: 2/10 (Consistent losses)
* Market performance: 3/10 (High volatility, negative price momentum)
* Volatility and risk: 2/10 (High volatility, low market depth)
* Corporate actions and governance: 5/10 (Stable shareholding, frequent investor communication)
* Shareholding patterns: 7/10 (Stable shareholding)

**Analysis Score (out of 10): 7**

* Completeness and utilization of all provided data: 8/10 (Most data used effectively)
* Accuracy and clarity of the analysis: 7/10 (Clear analysis, but limited by missing data)
* Professional formatting: 7/10 (Well-structured report)


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, MEDANTA is not recommended for investment in the short-term or long-term.  A medium-term "Hold" recommendation is given only for existing investors, contingent upon significant improvements in the company's financial performance and a clearer strategic direction.  The high volatility and consistent losses present significant risks that outweigh the potential rewards.  Further research is strongly recommended before making any investment decisions.  The lack of crucial financial ratios and detailed competitive analysis significantly limits the scope of this report.
